Figure 1. The expression pattern of B3GALT5-AS1 in colon cancer and its association with prognosis. (A) The expression intensity of B3GALT5-AS1 in 18 pairs of normal colonic epithelium, primary colorectal cancers, and metastasized cancers in liver from GSE50760. (B) The expression of B3GALT5-AS1 in 64 pairs of primary colon cancer tissues and adjacent colonic epithelium tissues was detected using qRT-PCR. P < 0.0001, Wilcoxon signed-rank test. (C) The expression of B3GALT5-AS1 in 15 colon cancer tissues with metastasis and 49 colon cancer tissues without metastasis. P < 0.0001, Mann-Whitney test. (D) The expression of B3GALT5-AS1 in 15 pairs of primary colon cancer tissues and corresponding liver metastasis tissues was measured using qRT-PCR. P < 0.0001, Wilcoxon signed-rank test. (E) Kaplan-Meier survival analysis of the correlation between B3GALT5-AS1 expression level and overall survival of 64 colon cancer patients. The median expression level of B3GALT5-AS1 was used as cut-off. P = 0.0096, Log-rank test. (F) The expression of B3GALT5-AS1 in normal colonic epithelial cell line NCM460 and colon cancer cell lines HCT116, HT-29, LoVo, SW480 and SW620 was measured using qRT-PCR. Results are displayed as mean ± s.d. of three independent experiments. **P < 0.01, ***P < 0.001, Student’s t-test.